drugset / Trial / NCT03683225

A Study to Evaluate in Patients With Parkinsonian Type Disorders

NCT03683225

Phase 2 Active not recruiting 24 enrolled Chase Therapeutics Corporation
NaSingle-groupOpen-labelTreatment

Summary

A Phase 2 study to evaluate the safety, tolerability and initial efficacy of pramipexole ER, given with aprepitant in patients with parkinsonian type disorders

Timeline

Start
2019-04-01
Primary completion
2025-12-30
Completion
2025-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Aprepitant Other / unclassified 80 mg Oral
Subject Pramipexole Unknown Oral

Indications